Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 17,832 matching trials from the live ClinicalTrials.gov search.

Filters: Chicago, Illinois Clear all

Conditions: Lymphoma
Interventions: Bendamustine, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, PCI-32765 (Ibrutinib), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 32
States / cities: Gilbert, Arizona • Campbell, California • Duarte, California + 29 more

Conditions: Osteoarthritis Post-meniscectomy
Interventions: Bone Marrow Aspirate Concentrate, Standard Meniscectomy; Biological · Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: hu14.18-IL2 fusion protein; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 54
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 44 more

Conditions: Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Fatigue, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions: modafinil, placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 6 Years to 19 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 60
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 53 more

Conditions: Hypertension
Interventions: carvedilol, metoprolol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 1,210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 50
States / cities: Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more

Conditions: Neoplasms
Interventions: MOXR0916; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 12
States / cities: Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 7 more

Conditions: Osteoarthritis, Knee
Interventions: MISHA Knee System, Non-Surgical Treatment; Device · Other
Lead sponsor: Moximed; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 9
States / cities: Davis, California • Oceanside, California • Sacramento, California + 6 more

Conditions: Excessive Sleepiness, Parkinson Disease
Interventions: JZP-110, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 25
States / cities: Los Angeles, California • San Diego, California • Boulder, Colorado + 22 more

Conditions: Multiple Myeloma
Interventions: MRZ 0.5 mg/m^2; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 6
States / cities: Tampa, Florida • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Healthy
Interventions: Active, Control; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Interventions: ThecaFlex DRx System; Device
Lead sponsor: Alcyone Therapeutics, Inc; Industry
Eligibility: 3 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 17
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 14 more

Conditions: Cardiopulmonary
Interventions: Not listed
Lead sponsor: Prolaio; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 11 more

Conditions: Urinary Urge Incontinence
Interventions: Revi System Treatment, Revi System - Delayed Activation; Device
Lead sponsor: BlueWind Medical; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: Tucson, Arizona • Pasadena, California • Riverside, California + 16 more

Conditions: Health Behavior
Interventions: HealtheRx; Other
Lead sponsor: University of Chicago; Other
Eligibility: 45 Years to 74 Years
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Autistic Disorder
Interventions: Fluoxetine (prozac); Drug
Lead sponsor: Neuropharm; Industry
Eligibility: 5 Years to 18 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Phoenix, Arizona • Sacramento, California • Smyrna, Georgia + 10 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: SGN-15, Docetaxel; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 9
States / cities: Los Angeles, California • Greenwich, Connecticut • Fort Myers, Florida + 5 more

Conditions: Chronic Pain
Interventions: Not listed
Lead sponsor: Telethon Kids Institute; Other
Eligibility: Up to 16 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 4 more

Conditions: HIV-1-Infection
Interventions: ISL/LEN, Antiretroviral Combinations; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more

Conditions: Neuroblastoma
Interventions: SF1126; Drug
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 30 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Colorectal Cancer
Interventions: ZD1839, oxaliplatin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 12
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more

Conditions: Cancer
Interventions: TrialTalk™; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • Charleston, South Carolina • Madison, Wisconsin

Conditions: Basal Cell Nevus Syndrome
Interventions: Patidegib Topical Gel, 2%; Drug
Lead sponsor: Sol-Gel Technologies, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Fremont, California • Newport Beach, California • New Haven, Connecticut + 14 more

Conditions: Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Interventions: Ecopipam; Drug
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 53
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 45 more

Conditions: Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions: Brimonidine 0.15%, Brimonidine 0.075%, Placebo; Drug
Lead sponsor: Sandeep Jain, MD; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois

Search by objective public record fields.

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy

Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors

Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension

A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors

MOTION Clinical Trial

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Effect of Orange Pomace Fiber on Glycemic Response

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

Observational, Non-Interventional Study Supporting Validation of eVO2peak Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)

RESTORE: An RCT to Evaluate the Efficacy of the Revi System

Study the Impact of the CommunityRx Program on Health, Self-care and Cost

Extended Management and Measurement of Autism

Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma

A Longitudinal Study Looking at the Prevalence, Risk Factors & Consequences of Persistent Post-surgical Pain in Children

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Evaluating the Communication Between Patients and Providers in Cancer Clinics

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)